Gilead Sciences Inc

GILD Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

$GILD is featured in our Shelley Moore Capito strategy.

See All Strategies
Income
Balance Sheet
Cash Flow
GILD Income Statement
GILD Balance Sheet
GILD Cash Flow
Congress Trading

Recent trades of GILD by members of U.S. Congress

Politician Type Traded
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 May. 10, 2024
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 May. 10, 2024
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 May. 10, 2024
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 May. 08, 2024
Tommy Tuberville Senate / R Purchase $1,001 - $15,000 Apr. 05, 2024
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 Apr. 03, 2024
HON. GREG STANTON House / D Sale $1,001 - $15,000 Oct. 24, 2023
HON. GREG STANTON House / D Purchase $1,001 - $15,000 Sep. 26, 2023
Daniel S. Goldman House / D Sale $15,001 - $50,000 Jul. 12, 2023
Zoe Lofgren House / D Sale $1,001 - $15,000 May. 25, 2023
Daniel S. Goldman House / D Purchase $15,001 - $50,000 Mar. 06, 2023
Zoe Lofgren House / D Purchase $1,001 - $15,000 Sep. 09, 2022
Tommy Tuberville Senate / R Sale (Full) $1,001 - $15,000 Jan. 13, 2022
Jerry Moran Senate / R Sale (Full) $1,001 - $15,000 Dec. 21, 2021
Jerry Moran Senate / R Sale (Full) $1,001 - $15,000 Dec. 21, 2021
Carol D. Miller House / R Sale $15,001 - $50,000 Nov. 10, 2021
Sara Jacobs House / D Sale $15,001 - $50,000 Apr. 09, 2021
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Jan. 21, 2021
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Dec. 22, 2020
Dean Phillips House / D Sale $1,001 - $15,000 Dec. 18, 2020
Dean Phillips House / D Purchase $1,001 - $15,000 Sep. 23, 2020
Ed Perlmutter House / D Sale $1,001 - $15,000 Sep. 01, 2020
Jerry Moran Senate / R Purchase $1,001 - $15,000 Aug. 21, 2020
Ed Perlmutter House / D Purchase $1,001 - $15,000 Jul. 15, 2020
William R. Timmons IV House / R Sale $1,001 - $15,000 Jun. 29, 2020
Roger Marshall House / R Purchase $1,001 - $15,000 May. 07, 2020
Roger Marshall House / R Purchase $1,001 - $15,000 May. 05, 2020
Roger Marshall House / R Purchase $1,001 - $15,000 May. 04, 2020
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Mar. 18, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 Feb. 20, 2020
Gilbert Ray Cisneros, Jr. House / D Purchase $1,001 - $15,000 Feb. 07, 2020
Mikie Sherrill House / D Purchase $1,001 - $15,000 Jan. 21, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 Dec. 18, 2019
Earl Blumenauer House / D Purchase $1,001 - $15,000 Oct. 25, 2019
Jerry Moran Senate / R Purchase $1,001 - $15,000 Sep. 25, 2019
Jerry Moran Senate / R Purchase $1,001 - $15,000 Sep. 25, 2019
Bill Flores House / R Purchase $1,001 - $15,000 Sep. 19, 2019
Dean Phillips House / D Sale $1,001 - $15,000 May. 13, 2019
Bill Flores House / R Sale $1,001 - $15,000 May. 08, 2019
Mikie Sherrill House / D Sale $1,001 - $15,000 Apr. 18, 2019
Bill Flores House / R Purchase $1,001 - $15,000 Mar. 25, 2019
Shelley Moore Capito Senate / R Sale (Full) $1,001 - $15,000 Mar. 11, 2019
Dean Phillips House / D Sale $1,001 - $15,000 Jan. 04, 2019
Greg Gianforte House / R Purchase $15,001 - $50,000 Dec. 21, 2018
Dean Heller Senate / R Sale (Full) $1,001 - $15,000 Dec. 06, 2018
John A. Yarmuth House / D Sale $1,001 - $15,000 Nov. 26, 2018
Shelley Moore Capito Senate / R Purchase $1,001 - $15,000 Sep. 25, 2018
Earl Blumenauer House / D Purchase $1,001 - $15,000 Jul. 17, 2018
Angus S. King Jr. Senate / I Sale (Partial) $1,001 - $15,000 Apr. 23, 2018
Dean Heller Senate / R Purchase $1,001 - $15,000 Mar. 16, 2018
GILD Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
GILD Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
GILD Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by GILD's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $2,050,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,530,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $2,740,000 Apr 18, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,680,000 Jan 23, 2024 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $2,390,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,440,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,490,000 Apr 14, 2023 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $2,520,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,372,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $2,620,000 Apr 20, 2022 Issue: Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark Medicare/Medicaid Health Issues Trade (domestic/foreign)
  • $1,980,000 Jan 19, 2022 Issue: None
  • $2,290,000 Oct 20, 2021 Issue: None
  • $1,380,000 Jul 20, 2021 Issue: None
  • $2,530,000 Apr 20, 2021 Issue: None
  • $1,510,000 Jan 20, 2021 Issue: None
  • $1,810,000 Oct 20, 2020 Issue: None
  • $1,260,000 Jul 20, 2020 Issue: None
  • $2,450,000 Apr 20, 2020 Issue: None
  • $1,300,000 Jan 21, 2020 Issue: None
  • $1,480,000 Oct 21, 2019 Issue: Budget/Appropriations Medicare/Medicaid Veterans Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Trade (domestic/foreign)
  • $1,080,000 Jul 22, 2019 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $1,860,000 Apr 23, 2019 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code Veterans Copyright/Patent/Trademark Health Issues
  • $700,000 Jan 22, 2019 Issue: Medicare/Medicaid Defense Trade (domestic/foreign) Copyright/Patent/Trademark Health Issues Veterans Budget/Appropriations Indian/Native American Affairs Taxation/Internal Revenue Code
  • $680,000 Oct 22, 2018 Issue: Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Indian/Native American Affairs Budget/Appropriations
  • $800,000 Jul 20, 2018 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Foreign Relations Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Veterans Trade (domestic/foreign)
  • $810,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Veterans Foreign Relations Indian/Native American Affairs Budget/Appropriations Taxation/Internal Revenue Code
  • $900,000 Jan 22, 2018 Issue: Indian/Native American Affairs Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Veterans Foreign Relations
  • $810,000 Oct 20, 2017 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Veterans Copyright/Patent/Trademark Foreign Relations Trade (domestic/foreign) Taxation/Internal Revenue Code Pharmacy Indian/Native American Affairs
  • $790,000 Jul 20, 2017 Issue: Pharmacy Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Veterans Trade (domestic/foreign) Indian/Native American Affairs Foreign Relations Taxation/Internal Revenue Code
  • $1,050,000 Apr 20, 2017 Issue: Law Enforcement/Crime/Criminal Justice Pharmacy Medicare/Medicaid Foreign Relations Health Issues Copyright/Patent/Trademark Indian/Native American Affairs Veterans Trade (domestic/foreign) Taxation/Internal Revenue Code Budget/Appropriations
  • $960,000 Jan 19, 2017 Issue: Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Budget/Appropriations Foreign Relations Trade (domestic/foreign) Law Enforcement/Crime/Criminal Justice Pharmacy
  • $780,000 Oct 20, 2016 Issue: Law Enforcement/Crime/Criminal Justice Pharmacy Medicare/Medicaid Foreign Relations Veterans Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Defense
  • $760,000 Jul 19, 2016 Issue: Medicare/Medicaid Foreign Relations Health Issues Pharmacy Trade (domestic/foreign) Veterans Defense Budget/Appropriations Copyright/Patent/Trademark
  • $980,000 Apr 18, 2016 Issue: Science/Technology Pharmacy Medicare/Medicaid Foreign Relations Veterans Health Issues Trade (domestic/foreign) Defense Budget/Appropriations Copyright/Patent/Trademark
  • $890,000 Jan 20, 2016 Issue: Science/Technology Pharmacy Medicare/Medicaid Health Issues Trade (domestic/foreign) Copyright/Patent/Trademark Veterans Foreign Relations Defense Budget/Appropriations
  • $700,000 Oct 19, 2015 Issue: Pharmacy Medicare/Medicaid Veterans Health Issues Defense Trade (domestic/foreign) Foreign Relations Budget/Appropriations Copyright/Patent/Trademark Science/Technology
  • $550,000 Jul 20, 2015 Issue: Science/Technology Pharmacy Medicare/Medicaid Veterans Health Issues Copyright/Patent/Trademark Defense Foreign Relations Budget/Appropriations Trade (domestic/foreign)
  • $800,000 Apr 21, 2015 Issue: Medicare/Medicaid Health Issues Veterans Trade (domestic/foreign) Defense Copyright/Patent/Trademark
  • $620,000 Jan 19, 2015 Issue: Medicare/Medicaid Health Issues Veterans Trade (domestic/foreign) Defense Copyright/Patent/Trademark
  • $640,000 Oct 17, 2014 Issue: Medicare/Medicaid Health Issues Veterans Trade (domestic/foreign) Copyright/Patent/Trademark
  • $820,000 Jul 15, 2014 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign)
  • $810,000 Apr 18, 2014 Issue: Medicare/Medicaid Veterans Health Issues Trade (domestic/foreign) Copyright/Patent/Trademark
  • $550,000 Jan 21, 2014 Issue: Health Issues Copyright/Patent/Trademark Veterans Medicare/Medicaid
  • $540,000 Oct 21, 2013 Issue: Health Issues Copyright/Patent/Trademark Veterans Medicare/Medicaid
  • $623,000 Aug 05, 2013 Issue: Health Issues Copyright/Patent/Trademark
  • $510,000 Jul 19, 2013 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign)
  • $320,000 Jan 22, 2013 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $370,000 Oct 22, 2012 Issue: Health Issues
  • $340,000 Jul 20, 2012 Issue: Health Issues
  • $560,000 Apr 20, 2012 Issue: Health Issues
  • $400,000 Jan 20, 2012 Issue: Health Issues
  • $370,000 Oct 20, 2011 Issue: Health Issues
  • $390,000 Jul 20, 2011 Issue: Health Issues
  • $500,000 Apr 20, 2011 Issue: Health Issues
  • $340,000 Jan 20, 2011 Issue: Health Issues
  • $350,000 Oct 20, 2010 Issue: Health Issues
  • $350,000 Jul 20, 2010 Issue: Health Issues
  • $480,000 Apr 20, 2010 Issue: Health Issues
  • $370,000 Jan 20, 2010 Issue: Health Issues
  • $350,000 Oct 20, 2009 Issue: Health Issues
  • $290,000 Jul 20, 2009 Issue: Health Issues
  • $270,000 Apr 20, 2009 Issue: Health Issues
  • $240,000 Jan 09, 2009 Issue: Health Issues
  • $240,000 Oct 28, 2008 Issue: Health Issues
  • $260,000 Oct 28, 2008 Issue: Health Issues
  • $260,000 Jun 25, 2008 Issue: Health Issues
  • $280,000 Feb 14, 2008 Issue: Health Issues
  • $380,000 Aug 14, 2007 Issue: Health Issues
  • $355,000 Feb 13, 2007 Issue: Health Issues
  • $455,000 Aug 14, 2006 Issue: Health Issues
  • $180,000 Apr 06, 2006 Issue: Health Issues
  • $60,000 Aug 24, 2005 Issue: Medical/Disease Research/Clinical Labs
  • $140,000 Aug 22, 2005 Issue: Health Issues
  • $20,000 Aug 15, 2005 Issue: Trade (domestic/foreign)
  • $40,000 Feb 09, 2005 Issue: None
  • $40,000 Sep 08, 2004 Issue: Health Issues
  • $100,000 Apr 12, 2004 Issue: Health Issues Pharmacy
  • $100,000 Aug 15, 2003 Issue: Health Issues Pharmacy
  • $100,000 Mar 03, 2003 Issue: Health Issues Pharmacy
  • $100,000 Aug 14, 2002 Issue: Health Issues Pharmacy
  • $60,000 Feb 14, 2002 Issue: Health Issues Pharmacy
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Lpa receptor antagonists and uses thereof Nov. 12, 2024
  • Patent Title: Tetracyclic compounds and uses thereof Oct. 22, 2024
  • Patent Title: Methods and intermediates for preparing therapeutic compounds Oct. 22, 2024
  • Patent Title: Ikaros zinc finger family degraders and uses thereof Oct. 22, 2024
  • Patent Title: Nucleoside phosphoramidate prodrugs Oct. 22, 2024
  • Patent Title: Glp-1r modulating compounds Oct. 22, 2024
  • Patent Title: Phospholipid compounds and methods of making and using the same Oct. 15, 2024
  • Patent Title: Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use Oct. 08, 2024
  • Patent Title: Cd73 compounds Oct. 08, 2024
  • Patent Title: Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies Oct. 01, 2024
  • Patent Title: Solid forms of fxr agonists Oct. 01, 2024
  • Patent Title: Sars-cov2 main protease inhibitors Sep. 17, 2024
  • Patent Title: Glp-1r modulating compounds Sep. 17, 2024
  • Patent Title: Antibodies selective for cells presenting egfr at high density Sep. 10, 2024
  • Patent Title: Therapeutic compounds for hiv virus infection Sep. 10, 2024
  • Patent Title: Hiv inhibitor compounds Sep. 10, 2024
  • Patent Title: Capsid inhibitors for the treatment of hiv Sep. 03, 2024
  • Patent Title: Thienopyrrole compounds Aug. 27, 2024
  • Patent Title: Compounds for the treatment of hiv Jun. 15, 2021
  • Patent Title: Phosphatidylinositol 3-kinase inhibitors Jun. 01, 2021
  • Patent Title: Methods for treating arenaviridae and coronaviridae virus infections May. 18, 2021
  • Patent Title: Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs Apr. 27, 2021
  • Patent Title: Mcl-1 inhibitors Apr. 27, 2021
  • Patent Title: Fxr (nr1h4) modulating compounds Apr. 20, 2021
  • Patent Title: Combination therapy comprising an acc inhibitor Apr. 20, 2021
  • Patent Title: Synthesis of polycyclic-carbamoylpyridone compounds Apr. 13, 2021
  • Patent Title: Process methods for phosphatidylinositol 3-kinase inhibitors Mar. 23, 2021
  • Patent Title: Cot modulators and methods of use thereof Mar. 16, 2021
  • Patent Title: Solid forms of an ask1 inhibitor Mar. 16, 2021
  • Patent Title: Method of purifying an antibody Mar. 09, 2021
  • Patent Title: 2′-substituted carba-nucleoside analogs for antiviral treatment Mar. 09, 2021
  • Patent Title: Pd-1/pd-l1 inhibitors Jan. 26, 2021
  • Patent Title: Multispecific antibodies that target hiv gp120 and cd3 Jan. 05, 2021
  • Patent Title: Human immunodeficiency virus neutralizing antibodies Jan. 05, 2021
  • Patent Title: 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections Jan. 05, 2021
  • Patent Title: Pyrrolo[1,2-b]pyridazine derivatives Dec. 29, 2020
  • Patent Title: Substituted pyrrolizine compounds and uses thereof Dec. 29, 2020
  • Patent Title: Antibodies and fragments thereof that bind hepatitis b virus protein x Dec. 22, 2020
  • Patent Title: Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate Dec. 08, 2020
  • Patent Title: Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-l-alaninate Dec. 01, 2020
  • Patent Title: Choline salt forms of an hiv capsid inhibitor Dec. 01, 2020
  • Patent Title: Multispecific antibodies that target hiv gp120 and cd3 Nov. 17, 2020
  • Patent Title: Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate Nov. 17, 2020
  • Patent Title: Substituted pyrrolizine compounds and uses thereof Nov. 17, 2020
  • Patent Title: Therapeutic compounds Nov. 17, 2020
  • Patent Title: Therapeutic compounds Oct. 13, 2020
  • Patent Title: Pd-1/pd-l1 inhibitors Sep. 15, 2020
  • Patent Title: Fxr (nr1h4) modulating compounds Sep. 15, 2020
  • Patent Title: Hiv protease inhibitors Sep. 15, 2020
  • Patent Title: Hiv inhibitor compounds Aug. 25, 2020
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of GILD in WallStreetBets Daily Discussion

GILD News

Recent insights relating to GILD

CNBC Recommendations

Recent picks made for GILD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in GILD

GILD Top Shareholders
Shareholder
Shares Held
GILD Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

GILD Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view GILD Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top